Jonathan Bye
Lawyers
Filters
RAPT Therapeutics $143.7 million follow-on offering
We advised the joint book-running managers on the SEC-registered equity offering
Nurix Therapeutics $160.4 million follow-on offering
We advised the underwriters on the equity offering
Electronic Arts $1.5 billion senior notes offering
We advised the underwriters in connection with the global notes offering
Surgalign Holdings $37.5 million follow-on offering
We advised the underwriters on the equity offering
IDEAYA Biosciences $90 million at-the-market offering
We advised the sales agent on the SEC-registered equity offering
RAPT Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its common stock for up to an aggregate amount of $100 million.
RAPT…
Maravai LifeSciences Holdings $1.863 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69,000,000 shares of Class A common stock of Maravai LifeSciences…
Five Prime Therapeutics $75 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million.
Five…
IDEAYA Biosciences $50 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its common stock for up to an aggregate amount of $50 million.
Based in…
Nurix Therapeutics $209 million IPO
Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of Nurix Therapeutics, Inc. at $19 per share, for total gross proceeds…